Aw, crud! Probably most of you would want to avert your eyes for this abbreviated week’s report. Or you can watch and see if I can manage to find *something* to be happy about.
NASDAQ down -2% for the week, biotech composites about the same or worse. Cutting straight to the portfolio stocks, all of the top performers were in the black this week (though none were in the YTD top performer list). In fact eleven stocks generated returns of more than +1% of their initial price. The best for the week was CDTX, up a healthy +27% of their initial price, with a big pop on Wednesday morning coincident with a press release that “promising interim efficacy and safety data from ongoing Phase 1 and 2a trials” triggering a $7 million milestone payment and "becoming eligible to receive an additional $685 million”.
Second place VKTX was up +15%, most of it on Friday, a delayed reaction, perhaps to the Thursday press release that they will be participating at two upcoming investor conferences. Or maybe, it was Wednesday’s press release announcing the initiation of a Phase 2 trial. For this week’s losers, JSPR accelerates its multi-week slide, sliding in fact right out of the top five YTD performers, slicing off another -48% of its initial value, All with no apparent news. Perhaps boredom. Second worse performer, CRVS (-45%), plunging at Thursday’s opening bell after a Company conference call and webcast an hour earlier. It’s YTD return dropped from second best to fourth, though a still respectable doubling of the original investment. PRVB and MOR by virtue of not tanking rose to second and third place YTD, replacing CRVS and JSPR. Now it appears even a return of +92% for the year (MGTA) is enough to enter the top five list.
The average portfolio shed another -$4.5k this week. In fact every contest portfolio was in the red for the week, although six outperformed the S&P Biotech Index. The best was GENEGURU, only losing -$1.4k, accomplished in spite of the fact of every one of their choices was a loser for the week, they avoided any BIG losers. Second place for the week is TOMATO, inching back into seventh place YTD. The higher spots on the ladder are unchanged from where last week’s tumult left them. Our first place portfolio for the year is still ALONER, now separated from second place ERKOTTO by $11k. ALONER managed a fifth place return for the week. Even though they had positive returns for the week coming in from holdings in both CDTX and KZIA, their gain was wiped out by their selection of CRVS.
Two of the stocks in my portfolio may be viewed as bottom feeders, like catfish, trying to see how low they can go. ENTA seems to have stabilized, but RVNC continues to disappoint. After two FDA approvals, they either have manufacturing issues, training issues, sales issues, pricing issues, or whatever. Wait ‘til next year. Time will tell.
Presenting at multiple investors conferences doesn’t help your case if your audience thinks they’ve heard it all already,
CDTX’s qualification for the milestone payment probably is something to feel happy about. At least ALONER, the sole contestant with a position in CDTX, should be happy as it helped keep him in first place YTD.
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 9/1/2023
| 9/8/23
|
|
|
|
|
|
|
|
| YTD
| 12/31/2022
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| -$2,582.42
| -1.9%
| $31,481.87
|
|
|
|
|
|
|
|
| ^NBI
| -$1,682.67
| -1.7%
| -$3,099.50
|
|
|
|
|
|
|
|
| ^SPSIBI
| -$2,918.55
| -3.0%
| -$5,241.76
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| CDTX
| 26.9%
| JSPR
| -47.6%
| INZY
| 359.0%
| AVTX
| -98.2%
| VKTX
| 14.7%
| CRVS
| -44.7%
| PRVB
| 136.5%
| APTA.L
| -97.5%
| KZIA
| 13.4%
| URGN
| -17.7%
| MOR
| 116.8%
| PTEIQ
| -87.2%
| ETON
| 9.9%
| PSNL
| -17.4%
| CRVS
| 105.9%
| ALT
| -85.1%
| MOR
| 9.5%
| PHAT
| -15.9%
| MGTA
| 92.0%
| TCON
| -84.3%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$4,498.86
| -$3,764.56
| RAJU_BIJLEE
|
| -$9,875.70
| -$14,221.13
| ARTHUR RADLEY
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - GENEGURU (10)
| -$1,421.55
| $1,497.01
| -$29,787.32 (13)
| 1 - ALONER (1)
| $32,556.20
| ——
| $37,797.96
| -$2,621.26 (5)
| 2 - TOMATO (9)
| -$2,295.72
| $622.84
| -$12,706.59 (7)
| 2 - ERIKOTTO (2)
| $21,339.88
| $11,216.32
| $26,581.64
| -$3,592.43 (7)
| 3 - BULBAMAN (11)
| -$2,343.82
| $574.74
| -$20,108.62 (11)
| 3 - RKRW (3)
| $20,416.55
| $12,139.66
| $25,658.31
| -$3,997.61 (9)
| 4 - BMAZ001 (8)
| -$2,388.72
| $529.84
| -$51,875.99 (15)
| 4 - STEVE LOKNESS (4)
| $14,519.43
| $18,036.77
| $19,761.20
| -$6,473.68 (12)
| 5 - ALONER (4)
| -$2,621.26
| $297.30
| $32,556.20 (1)
| 5 - BLADERUNNER (5)
| $6,919.15
| $25,637.05
| $12,160.91
| -$11,881.81 (15)
| 6 - TECHNETIUM (7)
| -$2,856.08
| $62.48
| -$16,497.60 (9)
| 6 - A.J. MULLEN (6)
| -$10,689.12
| $43,245.32
| -$5,447.36
| -$5,040.40 (11)
| 7 - ERIKOTTO (13)
| -$3,592.43
| -$673.88
| $21,339.88 (2)
| 7 - TOMATO (8)
| -$12,706.59
| $45,262.79
| -$7,464.83
| -$2,295.72 (2)
| Top Portfolios’ Contents
| Top Recent Performance Portfolio (GENEGURU)
| Top YTD Performance Portfolio (ALONER)
| Symbol (Rank)
| Current Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| AXSM
| 5.0%
| 7.4% | 4.6%
| $228.19
| -$67.42
| 19.1%
| AFMD
| 10%
| 4.3% | -55.2%
| -$6,966.57
| -$248.25
| 17.7%
| CMRX
| 5.0%
| 4.1% | -43.0%
| -$2,150.54
| -$40.32
| 35.1%
| CDTX
| 10%
| 11.8% | 23.9%
| $3,017.25
| $3,203.38
| 6.4%
| DCTH
| 20.0%
| 38.1% | 33.6%
| $6,722.22
| -$277.78
| 3.7%
| CLSD
| 10%
| 7.5% | -21.7%
| -$2,734.81
| -$575.25
| 10.1%
| GLYC
| 20.0%
| 13.9% | -51.2%
| -$10,231.02
| -$594.06
| 10.2%
| CRDF
| 10%
| 12.3% | 29.4%
| $3,717.18
| -$88.83
| 6.1%
| INVA
| 5.0%
| 6.8% | -4.8%
| -$237.74
| -$75.47
| 21.0%
| CRIS
| 10%
| 8.6% | -10.1%
| -$1,271.56
| -$1,094.78
| 8.8%
| MODD
| 5.0%
| 4.1% | -43.0%
| -$2,150.00
| -$50.00
| 35.1%
| CRVS
| 10%
| 18.6% | 95.0%
| $11,994.44
| -$5,346.58
| 4.1%
| PRQR
| 20.0%
| 11.9% | -58.4%
| -$11,675.68
| -$270.27
| 12.0%
| KZIA
| 10%
| 14.4% | 51.6%
| $6,516.95
| $1,495.64
| 5.2%
| XAIR
| 20.0%
| 13.8% | -51.5%
| -$10,292.76
| -$46.22
| 10.3%
| MGTA
| 10%
| 16.4% | 72.0%
| $9,092.02
| $406.73
| 4.6%
|
|
|
|
|
|
| MRNA
| 10%
| 6.2% | -35.3%
| -$4,460.53
| -$373.32
| 12.2%
|
|
|
|
|
|
| PRVB
| 10%
| 0.0% | 136.5%
| $13,651.84
| $0.00
| --
|
|
